Biopharma News

GSK is found guilty of offering bribes to doctors and is fined $489 million.

Baxter announced that its new biopharmaceutical company will be named Baxalta when the company separates into two publicly traded companies in mid-2015.

ProBioGen, a biopharmaceutical drug manufacturer in Berlin, spends ?20 million to double its workforce.

Pfizer announced that FDA approved ELELYSO for treatment of Type 1 Gaucher disease in adult and pediatric patients.

PSC Investments announces the acquisition of a high potency, sterile fill/finish pharmaceutical manufacturing facility.

CPhI 2014 panel additions to provide global insights from the contract services sector.

After rejecting several bids, Shire has agreed to a merger with AbbVie valued at almost $55 billion.

FDA grants breakthrough therapy designation to Novartis chimeric antigen receptor therapy.

PlantForm and PharmaPraxis announce plans to develop six biopharmaceutical targets for the Brazilian market.

Genentech's $1.7 billion acquisition of Seargon Pharmaceutical includes portfolio of investigational next-generation oral selective estrogen receptor degraders.

The collaboration will use Mersana Therapeutics Fleximer technology for antibody-drug conjugates.

Merck funds Bionomics with $20 million to progress therapies for cognitive impairment caused by central nervous system disorders

Bristol-Myers Squibb issues a voluntary US recall of Coumadin (warfarin sodium) for injection due to presence of particulate matter.

GSK and Save the Children announce criteria for awards that recognize innovation in healthcare for the world"s poorest children.

Cytovance Biologics completes GMP manufacture of ARMO BioSciences' lead product.

Medicenna Therapeutics selects Kalon Biotherapeutics to manufacture a new brain cancer drug for children and adults.

Shire reports that AbbVie offer undervalued company.

FDA cites cGMP violations for API manufacturing at a facility in Tianjin, China.

Novartis facility becomes the first US site licensed by the FDA to produce cell-culture influenza vaccines.

The new mAb manufacturing facility in Switzerland will supply material for clinical development.

Cellectis enters an agreement with CELLforCURE for cGMP clinical manufacturing of allogeneic T-cells.

Merck acquires Idenix Pharmaceuticals for $3.85 billion.

Provence Technologies? strengthens its expertise in therapeutic chemistry with acquisition of Synprosis.

PharmaCell has finalized its purchase of the cell therapy production facility from TiGenix.

Aastrom acquires Sanofi's CTRM business unit for $6.5 million.

Alexion initiates a voluntary nationwide recall of certain lots of soliris (eculizumab) concentrated solution for intravenous infusion because of visible particulate matter in a single lot.

GSK selects Genedata Biologics as an R&D data management and workflow-support platform.

Cytovance Biologics and Selexys Pharmaceuticals enter an agreement for development of clinical trial materials.

Kymab receives $40 million investment for clinical development of antibody therapeutics.

FDA issues complete response letter for Novartis' RLX030 for acute heart failure.